Physician profile
Anibal Melo
NPI 1861563421
$4,010.71
in general payments reported to CMS, 2019-2025
37 companies · $1,201 in 2025
The $1,201 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $122 · 2021: $180 · 2022: $518 · 2023: $814 · 2024: $976 · 2025: $1,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,989 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,988.68 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $904.51 | 2023-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $504.87 | 2019-2025 | Farxiga, Lokelma, Saphnelo |
| Philips North America LLC | $331.49 | 2019-2023 | |
| Vifor Pharma, INC. | $242.26 | 2019-2025 | Veltassa |
| Glaxosmithkline, LLC. | $226.80 | 2022-2025 | Benlysta, Arexvy, Shingrix |
| Horizon Therapeutics Plc | $224.45 | 2022-2023 | Krystexxa |
| Travere Therapeutics, INC. | $193.13 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $131.71 | 2019-2024 | Jynarque |
| Novartis Pharmaceuticals Corporation | $113.04 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.01 | 2022-2025 | |
| Viiv Healthcare Company | $111.59 | 2024-2025 | Rukobia, Apretude, Cabenuva |
| Outset Medical INC | $106.25 | 2021 | |
| Akebia Therapeutics INC | $97.15 | 2021-2022 | |
| Ucb, INC. | $86.83 | 2022-2025 | Bimzelx |
| Calliditas Therapeutics US INC. | $48.96 | 2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $46.74 | 2022 | |
| Paratek Pharmaceuticals, INC. | $46.28 | 2024 | Nuzyra |
| Scpharmaceuticals INC. | $42.43 | 2024-2025 | |
| Apellis Pharmaceuticals, INC. | $41.07 | 2025 | Empaveli |
| Vantive US Healthcare LLC | $38.17 | 2025 | Renal - Pd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.07 | 2024-2025 | Jardiance |
| Abbvie INC. | $31.72 | 2024 | |
| Merck Sharp & Dohme LLC | $30.92 | 2024 | Delstrigo, Dificid, Pifeltro |
| Pharmacosmos Therapeutics INC. | $25.47 | 2025 | Monoferric |
| Invivyd INC | $23.74 | 2025 | Pemgarda |
| Octapharma USA, INC. | $22.29 | 2024 | Octagam Immune Globulin (Human) |
| Alnylam Pharmaceuticals INC. | $21.88 | 2025 | Givlaari |
| Novo Nordisk INC | $21.11 | 2025 | Ozempic |
| Aimmune Therapeutics, INC. | $20.96 | 2025 | Vowst |
| Mallinckrodt Enterprises LLC | $19.10 | 2019 | |
| Janssen Biotech, INC. | $18.24 | 2022 | |
| Theratechnologies INC. | $17.56 | 2024 | Trogarzo, Egrifta |
| Ardelyx, INC. | $15.39 | 2024 | Ibsrela |
| Fresenius USA Marketing, INC. | $15.25 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $14.34 | 2024 | Vibativ |
| Pfizer INC. | $14.03 | 2025 | |
| Lilly USA, LLC | $13.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anibal Melo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.